Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Shitrit

Showing results (1-10 of 150) with videos related to

Pageof 15
Sort By:
Harefuah|May 24, 2012
[Challenges and trends in pulmonary medicine]David Shitrit
Harefuah|September 19, 2015
[Tuberculosis among patients in Israel with anti-TNF]Atamna Ahmed, Alexander Guber, David Shitrit
Presse Medicale (Paris, France : 1983)|January 4, 2011
The lung in rheumatoid arthritisAnat Amital, David Shitrit, Yochai Adir
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|April 28, 2020
"Severe-controlled" asthma 4 years later: is it still controlled?Shabtai Varsano, Lilach Israeli, David Shitrit
Respiratory Medicine|February 1, 2017
Severe and non-severe asthma in the community: A large electronic database analysisShabtai Varsano, David Segev, David Shitrit
The Israel Medical Association Journal : IMAJ|May 5, 2006
Pulmonary arterial hypertension associated with autoimmune disease: a single medical center experienceDaniele Bendayan, David Shitrit, Mordechai R Kramer
Harefuah|May 24, 2012
[Tracheobronchial adenoid cystic carcinoma: seven case reports]Victoria Rusanov, Mordechai R Kremer, David Shitrit
Respirology (Carlton, Vic.)|March 14, 2018
Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotypeGali Epstein Shochet, Lutz Wollin, David Shitrit
Respirology (Carlton, Vic.)|September 25, 2008
Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot studyDaniele Bendayan, David Shitrit, Mordechai R Kramer
International Journal of Molecular Sciences|August 12, 2023
Prostaglandin E2 (PGE2) and Roflumilast Involvement in IPF ProgressionNoa Moshkovitz, Gali Epstein Shochet, David Shitrit
Pageof 15

Showing results (1-10 of 150) with videos related to

Sort By:
Pageof 15
Harefuah|May 24, 2012
[Challenges and trends in pulmonary medicine]David Shitrit
Harefuah|September 19, 2015
[Tuberculosis among patients in Israel with anti-TNF]Atamna Ahmed, Alexander Guber, David Shitrit
Presse Medicale (Paris, France : 1983)|January 4, 2011
The lung in rheumatoid arthritisAnat Amital, David Shitrit, Yochai Adir
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|April 28, 2020
"Severe-controlled" asthma 4 years later: is it still controlled?Shabtai Varsano, Lilach Israeli, David Shitrit
Respiratory Medicine|February 1, 2017
Severe and non-severe asthma in the community: A large electronic database analysisShabtai Varsano, David Segev, David Shitrit
The Israel Medical Association Journal : IMAJ|May 5, 2006
Pulmonary arterial hypertension associated with autoimmune disease: a single medical center experienceDaniele Bendayan, David Shitrit, Mordechai R Kramer
Harefuah|May 24, 2012
[Tracheobronchial adenoid cystic carcinoma: seven case reports]Victoria Rusanov, Mordechai R Kremer, David Shitrit
Respirology (Carlton, Vic.)|March 14, 2018
Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotypeGali Epstein Shochet, Lutz Wollin, David Shitrit
Respirology (Carlton, Vic.)|September 25, 2008
Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot studyDaniele Bendayan, David Shitrit, Mordechai R Kramer
International Journal of Molecular Sciences|August 12, 2023
Prostaglandin E2 (PGE2) and Roflumilast Involvement in IPF ProgressionNoa Moshkovitz, Gali Epstein Shochet, David Shitrit
Pageof 15